EyePoint, Inc (EYPT)vsModerna Inc (MRNA)
EYPT
EyePoint, Inc
$4.23
-0.47%
HEALTHCARE · Cap: $374.16M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 79814% more annual revenue ($2.23B vs $2.79M). EYPT leads profitability with a 0.0% profit margin vs -141.4%. EYPT earns a higher WallStSmart Score of 35/100 (F).
EYPT
Hold35
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EYPT.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 161.7% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 10.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EYPT
The strongest argument for EYPT centers on Revenue Growth, Debt/Equity. Revenue growth of 161.7% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : EYPT
The primary concerns for EYPT are Price/Book, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
EYPT profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
EYPT carries more volatility with a beta of 1.64 — expect wider price swings.
EYPT is growing revenue faster at 161.7% — sustainability is the question.
EYPT generates stronger free cash flow (-64M), providing more financial flexibility.
Bottom Line
EYPT scores higher overall (35/100 vs 21/100) and 161.7% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EyePoint, Inc
HEALTHCARE · BIOTECHNOLOGY · USA
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?